Your trusted source for investing success
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
GeoVax Labs announced it is providing an updated presentation of results from studies of GeoVax’s NS-1 based Zika vaccine during the Vaccine Congress conference.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
GeoVax Labs announced their chief scientific officer, Dr. Farshad Guirakhoo presented the company’s results in its studies of their NS-1 based Zika vaccine.
GeoVax Labs announced their chief scientific officer, Dr. Farshad Guirakhoo will give two talks during the Immuno-Oncology Summit on the company’s vaccine programs.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
As investors look ahead at the remainder of 2017, the INN put together a list of the top gaining pharmaceutical stocks on the Toronto Stock Exchange.
The race to find cannabis-based treatments is on, and Alternate Health took a major step forward with a post-Zika study.
Breathtec BioMedical gave a corporate update to shareholders on recent events and provided an outlook on the company’s future plans.
Alternate Health announced the completion of a study to investigate the potential of using cannabinoid for treating post-Zik virus symptoms.
GeoVax Labs released their financial results for the first quarter of 2017 and gave updates on the state of its various vaccines.
Immunovaccine announced the dosing of the first patient for their investigational cancer vaccine clinical study.
The Investing News Network takes a look at some of the best-performing pharmaceutical stocks on the TSX during the first quarter of 2017.
Immunovaccine provided new data from a Phase I trial testing safety and immunogenicity of its DepoVax-based, small B-cell epitope peptide vaccine candidate for respiratory syncytial virus.
GeoVax Labs received a grant for $658,159 from the National Institute of Allergy and Infectious Disease in support of its HIV vaccine development program.
Immunovaccine (TSX:IMV, OTCQX:IMMVF) announced its financial and operational results for 2016.
